{"name":"CareCanon FDA label changes dataset","description":"Dated entries from the Recent Major Changes sections of FDA prescribing labels tracked by CareCanon.","canonical":"https://carecanon.com/label-changes","methodology":"https://carecanon.com/methodology","sourcePublisher":"DailyMed, U.S. National Library of Medicine","generatedAt":"2026-08-29T19:54:32.487Z","recordCount":20,"labelCount":5,"fields":["recordId","brand","ingredient","setid","labelPublished","retrievedAt","sourceUrl","section","label","revised"],"records":[{"recordId":"ee06186f-2aa3-4990-a760-757579d8f77b:5.11:06/2026:Never Share WEGOVY FlexTouch Between Patients","brand":"WEGOVY","slug":"wegovy","ingredient":"semaglutide","setid":"ee06186f-2aa3-4990-a760-757579d8f77b","labelPublished":"Jun 30, 2026","retrievedAt":"2026-08-29T19:54:27.703Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b","section":"5.11","label":"Never Share WEGOVY FlexTouch Between Patients","revised":"06/2026"},{"recordId":"487cd7e7-434c-4925-99fa-aa80b1cc776b:5.2:02/2026:Warnings and Precautions Severe Gastrointestinal Adverse Reactions","brand":"ZEPBOUND","slug":"zepbound","ingredient":"tirzepatide","setid":"487cd7e7-434c-4925-99fa-aa80b1cc776b","labelPublished":"May 06, 2026","retrievedAt":"2026-08-29T19:54:31.296Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b","section":"5.2","label":"Warnings and Precautions Severe Gastrointestinal Adverse Reactions","revised":"02/2026"},{"recordId":"487cd7e7-434c-4925-99fa-aa80b1cc776b:2.4:01/2026:Dosage and Administration","brand":"ZEPBOUND","slug":"zepbound","ingredient":"tirzepatide","setid":"487cd7e7-434c-4925-99fa-aa80b1cc776b","labelPublished":"May 06, 2026","retrievedAt":"2026-08-29T19:54:31.296Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b","section":"2.4","label":"Dosage and Administration","revised":"01/2026"},{"recordId":"487cd7e7-434c-4925-99fa-aa80b1cc776b:5.10:01/2026:Never Share a ZEPBOUND KwikPen Between Patients","brand":"ZEPBOUND","slug":"zepbound","ingredient":"tirzepatide","setid":"487cd7e7-434c-4925-99fa-aa80b1cc776b","labelPublished":"May 06, 2026","retrievedAt":"2026-08-29T19:54:31.296Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b","section":"5.10","label":"Never Share a ZEPBOUND KwikPen Between Patients","revised":"01/2026"},{"recordId":"d2d7da5d-ad07-4228-955f-cf7e355c8cc0:2.2:01/2026:Important Administration Instructions","brand":"MOUNJARO","slug":"mounjaro","ingredient":"tirzepatide","setid":"d2d7da5d-ad07-4228-955f-cf7e355c8cc0","labelPublished":"May 06, 2026","retrievedAt":"2026-08-29T19:54:32.487Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0","section":"2.2","label":"Important Administration Instructions","revised":"01/2026"},{"recordId":"d2d7da5d-ad07-4228-955f-cf7e355c8cc0:5.10:01/2026:Never Share a MOUNJARO KwikPen Between Patients","brand":"MOUNJARO","slug":"mounjaro","ingredient":"tirzepatide","setid":"d2d7da5d-ad07-4228-955f-cf7e355c8cc0","labelPublished":"May 06, 2026","retrievedAt":"2026-08-29T19:54:32.487Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0","section":"5.10","label":"Never Share a MOUNJARO KwikPen Between Patients","revised":"01/2026"},{"recordId":"27f15fac-7d98-4114-a2ec-92494a91da98:2:12/2025:Dosage and Administration","brand":"RYBELSUS","slug":"rybelsus","ingredient":"semaglutide","setid":"27f15fac-7d98-4114-a2ec-92494a91da98","labelPublished":"Aug 19, 2026","retrievedAt":"2026-08-29T19:54:30.107Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98","section":"2","label":"Dosage and Administration","revised":"12/2025"},{"recordId":"d2d7da5d-ad07-4228-955f-cf7e355c8cc0:1:12/2025:Indications and Usage","brand":"MOUNJARO","slug":"mounjaro","ingredient":"tirzepatide","setid":"d2d7da5d-ad07-4228-955f-cf7e355c8cc0","labelPublished":"May 06, 2026","retrievedAt":"2026-08-29T19:54:32.487Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0","section":"1","label":"Indications and Usage","revised":"12/2025"},{"recordId":"d2d7da5d-ad07-4228-955f-cf7e355c8cc0:2.1:12/2025:Recommended Dosage","brand":"MOUNJARO","slug":"mounjaro","ingredient":"tirzepatide","setid":"d2d7da5d-ad07-4228-955f-cf7e355c8cc0","labelPublished":"May 06, 2026","retrievedAt":"2026-08-29T19:54:32.487Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0","section":"2.1","label":"Recommended Dosage","revised":"12/2025"},{"recordId":"d2d7da5d-ad07-4228-955f-cf7e355c8cc0:5.6:12/2025:Warnings and Precautions Severe Gastrointestinal Adverse Reactions","brand":"MOUNJARO","slug":"mounjaro","ingredient":"tirzepatide","setid":"d2d7da5d-ad07-4228-955f-cf7e355c8cc0","labelPublished":"May 06, 2026","retrievedAt":"2026-08-29T19:54:32.487Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0","section":"5.6","label":"Warnings and Precautions Severe Gastrointestinal Adverse Reactions","revised":"12/2025"},{"recordId":"ee06186f-2aa3-4990-a760-757579d8f77b:5.6:10/2025:Severe Gastrointestinal Adverse Reactions","brand":"WEGOVY","slug":"wegovy","ingredient":"semaglutide","setid":"ee06186f-2aa3-4990-a760-757579d8f77b","labelPublished":"Jun 30, 2026","retrievedAt":"2026-08-29T19:54:27.703Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b","section":"5.6","label":"Severe Gastrointestinal Adverse Reactions","revised":"10/2025"},{"recordId":"adec4fd2-6858-4c99-91d4-531f5f2a2d79:5.7:10/2025:Warnings and Precautions, Severe Gastrointestinal Adverse Reactions","brand":"OZEMPIC","slug":"ozempic","ingredient":"semaglutide","setid":"adec4fd2-6858-4c99-91d4-531f5f2a2d79","labelPublished":"Jun 10, 2026","retrievedAt":"2026-08-29T19:54:28.918Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79","section":"5.7","label":"Warnings and Precautions, Severe Gastrointestinal Adverse Reactions","revised":"10/2025"},{"recordId":"27f15fac-7d98-4114-a2ec-92494a91da98:1:10/2025:Indications and Usage","brand":"RYBELSUS","slug":"rybelsus","ingredient":"semaglutide","setid":"27f15fac-7d98-4114-a2ec-92494a91da98","labelPublished":"Aug 19, 2026","retrievedAt":"2026-08-29T19:54:30.107Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98","section":"1","label":"Indications and Usage","revised":"10/2025"},{"recordId":"27f15fac-7d98-4114-a2ec-92494a91da98:5.2:10/2025:Warnings and Precautions Acute Pancreatitis","brand":"RYBELSUS","slug":"rybelsus","ingredient":"semaglutide","setid":"27f15fac-7d98-4114-a2ec-92494a91da98","labelPublished":"Aug 19, 2026","retrievedAt":"2026-08-29T19:54:30.107Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98","section":"5.2","label":"Warnings and Precautions Acute Pancreatitis","revised":"10/2025"},{"recordId":"27f15fac-7d98-4114-a2ec-92494a91da98:5.5:10/2025:Acute Kidney Injury Due to Volume Depletion","brand":"RYBELSUS","slug":"rybelsus","ingredient":"semaglutide","setid":"27f15fac-7d98-4114-a2ec-92494a91da98","labelPublished":"Aug 19, 2026","retrievedAt":"2026-08-29T19:54:30.107Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98","section":"5.5","label":"Acute Kidney Injury Due to Volume Depletion","revised":"10/2025"},{"recordId":"27f15fac-7d98-4114-a2ec-92494a91da98:5.6:10/2025:Severe Gastrointestinal Adverse Reactions","brand":"RYBELSUS","slug":"rybelsus","ingredient":"semaglutide","setid":"27f15fac-7d98-4114-a2ec-92494a91da98","labelPublished":"Aug 19, 2026","retrievedAt":"2026-08-29T19:54:30.107Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98","section":"5.6","label":"Severe Gastrointestinal Adverse Reactions","revised":"10/2025"},{"recordId":"27f15fac-7d98-4114-a2ec-92494a91da98:5.8:10/2025:Acute Gallbladder Disease","brand":"RYBELSUS","slug":"rybelsus","ingredient":"semaglutide","setid":"27f15fac-7d98-4114-a2ec-92494a91da98","labelPublished":"Aug 19, 2026","retrievedAt":"2026-08-29T19:54:30.107Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98","section":"5.8","label":"Acute Gallbladder Disease","revised":"10/2025"},{"recordId":"ee06186f-2aa3-4990-a760-757579d8f77b:1:08/2025:Indications and Usage","brand":"WEGOVY","slug":"wegovy","ingredient":"semaglutide","setid":"ee06186f-2aa3-4990-a760-757579d8f77b","labelPublished":"Jun 30, 2026","retrievedAt":"2026-08-29T19:54:27.703Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b","section":"1","label":"Indications and Usage","revised":"08/2025"},{"recordId":"ee06186f-2aa3-4990-a760-757579d8f77b:2:08/2025:Dosage and Administration","brand":"WEGOVY","slug":"wegovy","ingredient":"semaglutide","setid":"ee06186f-2aa3-4990-a760-757579d8f77b","labelPublished":"Jun 30, 2026","retrievedAt":"2026-08-29T19:54:27.703Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b","section":"2","label":"Dosage and Administration","revised":"08/2025"},{"recordId":"ee06186f-2aa3-4990-a760-757579d8f77b:5.5:08/2025:Warnings and Precautions, Acute Kidney Injury due to Volume Depletion","brand":"WEGOVY","slug":"wegovy","ingredient":"semaglutide","setid":"ee06186f-2aa3-4990-a760-757579d8f77b","labelPublished":"Jun 30, 2026","retrievedAt":"2026-08-29T19:54:27.703Z","sourceUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b","section":"5.5","label":"Warnings and Precautions, Acute Kidney Injury due to Volume Depletion","revised":"08/2025"}]}